Title (COG AAML1031) A Phase III Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for Patients with High Allelic Ratio FLT3/ITD
Principal Investigator Lynda Beaupin, MD
Study Number 217112
Summary To compare event free survival and overall survival in patients with de novo acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD + mutations who are randomized to standard therapy versus bortezomib/standard combination therapy. To determine the feasibility of combining bortezomib with standard chemotherapy in patients with de nova AML.
Eligibility See Clinicaltrials.gov link for current Eligibility criteria.